Viking Therapeutics (VKTX) is a publicly traded Healthcare sector company. As of October 4, 2026, VKTX trades at $30.02 with a market cap of $3.76B and a P/E ratio of -9.41. VKTX moved -1.87% today. Year to date, VKTX is -15.47%; over the trailing twelve months it is +7.39%. Its 52-week range spans $18.92 to $43.15. Analyst consensus is strong buy with an average price target of $92.19. Rallies surfaces VKTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Viking Therapeutics closes $292.5 million convertible senior notes offering: Viking Therapeutics closed a $258.75 million offering of 2.00% convertible senior notes due 2032, with underwriters exercising their option for an additional $33.75 million. Gross proceeds totaled $292.5 million, while net proceeds from concurrent stock and note offerings were about $547.8 million.
| Metric | Value |
|---|---|
| Price | $30.02 |
| Market Cap | $3.76B |
| P/E Ratio | -9.41 |
| EPS | $-3.19 |
| Dividend Yield | 0.00% |
| 52-Week High | $43.15 |
| 52-Week Low | $18.92 |
| Volume | 5.62M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-359.64M |
| Gross Margin | 0.00% |
17 analysts cover VKTX: 0 strong buy, 16 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $92.19.